DK3630977T3 - Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer - Google Patents

Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer Download PDF

Info

Publication number: DK3630977T3
Authority: DK; Denmark
Prior art keywords: promoting; compositions; production; methods; amino acids
Prior art date: 2017-06-02

Application number

DK18734359.5T

Other languages

English (en)

Other versions

DK3630977T5 (da

Inventor

Sigeng Chen

Yingchun Lu

Feng Tian

Original Assignee

Ambrx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-02

Filing date

2018-06-02

Publication date

2024-04-15

2018-06-02 Application filed by Ambrx Inc filed Critical Ambrx Inc

2024-04-15 Application granted granted Critical

2024-04-15 Publication of DK3630977T3 publication Critical patent/DK3630977T3/da

2024-09-02 Publication of DK3630977T5 publication Critical patent/DK3630977T5/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Reproductive Health (AREA)
Public Health (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK18734359.5T 2017-06-02 2018-06-02 Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer DK3630977T5 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762514754P	2017-06-02	2017-06-02
PCT/US2018/035764 WO2018223108A1 (en)	2017-06-02	2018-06-02	Methods and compositions for promoting non-natural amino acid-containing protein production

Publications (2)

Publication Number	Publication Date
DK3630977T3 true DK3630977T3 (da)	2024-04-15
DK3630977T5 DK3630977T5 (da)	2024-09-02

Family

ID=62749186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18734359.5T DK3630977T5 (da)	2017-06-02	2018-06-02	Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer

Country Status (23)

Country	Link
US (2)	US11851662B2 (da)
EP (2)	EP4382124A3 (da)
JP (3)	JP7245786B2 (da)
KR (3)	KR102705871B1 (da)
CN (2)	CN110959041B (da)
AU (1)	AU2018275152B2 (da)
BR (1)	BR112019025476A2 (da)
CA (1)	CA3065137A1 (da)
DK (1)	DK3630977T5 (da)
ES (1)	ES2978044T3 (da)
FI (1)	FI3630977T3 (da)
HR (1)	HRP20240344T1 (da)
HU (1)	HUE067136T2 (da)
IL (1)	IL270906A (da)
LT (1)	LT3630977T (da)
MX (2)	MX2019014286A (da)
MY (1)	MY202215A (da)
PL (1)	PL3630977T3 (da)
PT (1)	PT3630977T (da)
RS (1)	RS65370B1 (da)
SI (1)	SI3630977T1 (da)
SM (1)	SMT202400125T1 (da)
WO (1)	WO2018223108A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS65370B1 (sr) *	2017-06-02	2024-04-30	Ambrx Inc	Metode i kompozicije za unapređenje proizvodnje proteina koji sadrže neprirodne aminokiseline
WO2019191728A1 (en)	2018-03-29	2019-10-03	Ambrx, Inc.	Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
MX2021002575A (es)	2018-09-11	2021-06-08	Ambrx Inc	Conjugados de polipeptidos de interleucina-2 y sus usos.
KR102910209B1 (ko) *	2018-12-21	2026-01-09	제넨테크, 인크.	세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
CN111117944B (zh) *	2019-11-22	2022-05-24	中农威特生物科技股份有限公司	一种用于规模化悬浮培养的抗凋亡mdck宿主细胞株及其建立方法
WO2021262783A1 (en) *	2020-06-24	2021-12-30	Genentech, Inc.	Apoptosis resistant cell lines
CN112375774A (zh) *	2020-10-26	2021-02-19	浙江新码生物医药有限公司	一种重组蛋白表达用工程菌株的构建方法
CN112575005A (zh) *	2021-01-04	2021-03-30	昆明理工大学	一种提高烟草重金属镉胁迫抗性和降低镉富集的方法
KR20240141757A (ko)	2022-02-09	2024-09-27	다이이찌 산쿄 가부시키가이샤	환경 응답성 마스킹 항체 및 그 이용
WO2023202967A1 (en) *	2022-04-19	2023-10-26	F. Hoffmann-La Roche Ag	Improved production cells
IL322121A (en)	2023-01-16	2025-09-01	Ambrx Inc	Anti-CD70 antibody-drug conjugates
AR131133A1 (es)	2023-05-24	2025-02-19	Ambrx Inc	INTERFERÓN l BOVINO PEGILADO Y MÉTODOS DE USO DEL MISMO
WO2025041055A1 (en)	2023-08-22	2025-02-27	Ambrx, Inc.	Anti-psma adc conjugate compositions and methods of use thereof
WO2025147710A1 (en) *	2024-01-05	2025-07-10	Northwestern University	Orthogonal translation systems and methods for identifying components thereof
WO2026058210A1 (en) *	2024-09-12	2026-03-19	Janssen Biotech, Inc.	Model system and biomarkers to prevent lactate runaway
CN121652263A (zh) *	2026-02-06	2026-03-13	中国医学科学院北京协和医院	非天然氨基酸修饰的蛋白质及相关生物材料、制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL158418A0 (en)	2001-04-19	2004-05-12	Scripps Research Inst	In vivo incorporation of unnatural amino acids
MXPA05006836A (es)	2002-12-22	2005-08-16	Scripps Research Inst	Colecciones ordenadas de proteinas.
CN101160525A (zh) *	2003-06-18	2008-04-09	斯克利普斯研究院	非天然活性氨基酸遗传密码增加
BRPI0411475A (pt)	2003-06-18	2006-07-25	Scripps Research Inst	adições de código genético de aminoácido reativo não natural
NZ555425A (en)	2004-12-22	2010-04-30	Ambrx Inc	Compositions of aminoacyl-tRNA synthetase and uses thereof
CA2618878C (en)	2005-08-18	2016-06-28	Ambrx, Inc.	Compositions of trna and uses thereof
EP1951890A4 (en) *	2005-11-16	2009-06-24	Ambrx Inc	PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
KR101423898B1 (ko)	2005-12-14	2014-07-28	암브룩스, 인코포레이티드	비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
PT2064333E (pt)	2006-09-08	2014-06-09	Ambrx Inc	Supressor híbrido arnt para células de vertebrados
ES2457527T3 (es)	2006-09-08	2014-04-28	Ambrx, Inc.	ARNt Supresor hibrido en células de vertebrados
US20100093082A1 (en)	2006-09-08	2010-04-15	Ambrx, Inc.	Site Specific Incorporation of Non-Natural Amino Acids by Vertebrate Cells
KR20090094812A (ko)	2006-10-18	2009-09-08	더 스크립스 리서치 인스티튜트	포유동물 세포에서 비천연 아미노산의 단백질 내로의 유전적 도입
WO2008127900A1 (en) *	2007-04-13	2008-10-23	The Salk Institute For Biological Studies	Methods of genetically encoding unnatural amino acids in eukaryotic cells using orthogonal trna/synthetase pairs
US8142788B2 (en)	2007-04-30	2012-03-27	Mj Biologics, Inc.	PRRSV GP5 based compositions and methods
GB0721291D0 (en) *	2007-10-30	2007-12-12	Medical Res Council	Methods and compositions
EP2294191B1 (en) *	2008-06-10	2016-09-28	Sangamo BioSciences, Inc.	Methods and compositions for generation of bax- and bak-deficient cell lines
US20120077224A1 (en)	2009-06-05	2012-03-29	The Salk Institute For Biological Studies	unnatural amino acid incorporation in eukaryotic cells
WO2013130814A1 (en)	2012-02-29	2013-09-06	Ambrx, Inc.	Novel prodrug containing molecule compostions and their uses
MX363116B (es)	2012-06-07	2019-03-11	Ambrx Inc	Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
AU2013274078A1 (en)	2012-06-14	2015-01-29	Ambrx, Inc.	Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
EP4406612A3 (en)	2012-06-19	2024-10-16	Ambrx, Inc.	Anti-cd70 antibody drug conjugates
GB201419109D0 (en) *	2014-10-27	2014-12-10	Medical Res Council	Incorporation of unnatural amino acids into proteins
RS65370B1 (sr)	2017-06-02	2024-04-30	Ambrx Inc	Metode i kompozicije za unapređenje proizvodnje proteina koji sadrže neprirodne aminokiseline

2018
- 2018-06-02 RS RS20240405A patent/RS65370B1/sr unknown
- 2018-06-02 ES ES18734359T patent/ES2978044T3/es active Active
- 2018-06-02 PT PT187343595T patent/PT3630977T/pt unknown
- 2018-06-02 MY MYPI2019007098A patent/MY202215A/en unknown
- 2018-06-02 KR KR1020247014001A patent/KR102705871B1/ko active Active
- 2018-06-02 EP EP24158417.6A patent/EP4382124A3/en active Pending
- 2018-06-02 HR HRP20240344TT patent/HRP20240344T1/hr unknown
- 2018-06-02 WO PCT/US2018/035764 patent/WO2018223108A1/en not_active Ceased
- 2018-06-02 BR BR112019025476-5A patent/BR112019025476A2/pt unknown
- 2018-06-02 JP JP2019565862A patent/JP7245786B2/ja active Active
- 2018-06-02 AU AU2018275152A patent/AU2018275152B2/en not_active Expired - Fee Related
- 2018-06-02 PL PL18734359.5T patent/PL3630977T3/pl unknown
- 2018-06-02 HU HUE18734359A patent/HUE067136T2/hu unknown
- 2018-06-02 MX MX2019014286A patent/MX2019014286A/es unknown
- 2018-06-02 US US16/958,152 patent/US11851662B2/en active Active
- 2018-06-02 KR KR1020247030044A patent/KR20240140174A/ko active Pending
- 2018-06-02 SM SM20240125T patent/SMT202400125T1/it unknown
- 2018-06-02 CN CN201880049275.0A patent/CN110959041B/zh active Active
- 2018-06-02 CA CA3065137A patent/CA3065137A1/en active Pending
- 2018-06-02 KR KR1020197038544A patent/KR102662379B1/ko active Active
- 2018-06-02 LT LTEPPCT/US2018/035764T patent/LT3630977T/lt unknown
- 2018-06-02 DK DK18734359.5T patent/DK3630977T5/da active
- 2018-06-02 CN CN202311164969.8A patent/CN117286182A/zh active Pending
- 2018-06-02 SI SI201831076T patent/SI3630977T1/sl unknown
- 2018-06-02 FI FIEP18734359.5T patent/FI3630977T3/fi active
- 2018-06-02 EP EP18734359.5A patent/EP3630977B1/en active Active
2019
- 2019-11-25 IL IL270906A patent/IL270906A/en unknown
- 2019-11-28 MX MX2023004927A patent/MX2023004927A/es unknown
2023
- 2023-03-13 JP JP2023038441A patent/JP7617162B2/ja active Active
- 2023-11-10 US US18/506,836 patent/US12577575B2/en active Active
2025
- 2025-01-06 JP JP2025001705A patent/JP2025061014A/ja active Pending

Also Published As

Publication number	Publication date
US11851662B2 (en)	2023-12-26
KR20200011979A (ko)	2020-02-04
MX2019014286A (es)	2020-01-27
PT3630977T (pt)	2024-04-24
KR102705871B1 (ko)	2024-09-11
ES2978044T3 (es)	2024-09-04
CN117286182A (zh)	2023-12-26
EP3630977B1 (en)	2024-02-21
EP3630977A1 (en)	2020-04-08
LT3630977T (lt)	2024-04-25
US20240167044A1 (en)	2024-05-23
KR20240140174A (ko)	2024-09-24
HRP20240344T1 (hr)	2024-05-24
EP4382124A3 (en)	2024-10-16
JP7245786B2 (ja)	2023-03-24
SI3630977T1 (sl)	2024-05-31
JP7617162B2 (ja)	2025-01-17
KR102662379B1 (ko)	2024-04-29
WO2018223108A1 (en)	2018-12-06
HUE067136T2 (hu)	2024-10-28
AU2018275152A1 (en)	2020-01-16
BR112019025476A2 (pt)	2020-06-23
MX2023004927A (es)	2023-05-17
NZ760107A (en)	2024-03-22
FI3630977T3 (fi)	2024-04-24
IL270906A (en)	2020-01-30
CN110959041A (zh)	2020-04-03
JP2020522247A (ja)	2020-07-30
RS65370B1 (sr)	2024-04-30
DK3630977T5 (da)	2024-09-02
JP2023075254A (ja)	2023-05-30
PL3630977T3 (pl)	2024-06-24
US12577575B2 (en)	2026-03-17
KR20240063184A (ko)	2024-05-09
JP2025061014A (ja)	2025-04-10
SMT202400125T1 (it)	2024-05-14
MY202215A (en)	2024-04-17
AU2018275152B2 (en)	2025-01-23
CN110959041B (zh)	2023-09-29
EP4382124A2 (en)	2024-06-12
US20210017527A1 (en)	2021-01-21
CA3065137A1 (en)	2018-12-06

Publication	Publication Date	Title
DK3630977T5 (da)	2024-09-02	Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer
DK3601533T3 (da)	2021-05-03	Fremgangsmåder til frembringelse af tumorinfiltrerende lymfocytter og anvendelser af samme i immunoterapi
DK3303317T3 (da)	2021-12-13	Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
DK3272867T3 (da)	2019-12-02	Anvendelse af programmerbare dna-bindingsproteiner til forbedring af målrettet genommodifikation
DK3232806T3 (da)	2020-11-30	Opløsning af denatureret ærteprotein og anvendelser deraf til dannelse af mikropartikler
DK3298043T3 (da)	2021-02-15	SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
DK3390444T3 (da)	2026-02-23	Anti-tl1a-antigenbindende proteiner og anvendelser deraf
EP3576782A4 (en)	2020-12-30	COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
EP3595699A4 (en)	2020-12-23	PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
DK3389636T3 (da)	2022-09-19	Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
DK3240895T3 (da)	2022-04-11	Sammensætninger og fremgangsmåder til proteinglykosylering
GB201419109D0 (en)	2014-12-10	Incorporation of unnatural amino acids into proteins
DK3649104T3 (da)	2022-01-10	Fremgangsmåde til fremstilling af langkædede aminosyrer og dibasiske syrer
DK3565579T3 (da)	2023-09-04	Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3565828T3 (da)	2022-02-21	Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3313864T3 (da)	2021-11-01	Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
IL253971A0 (en)	2017-10-31	A method for purifying fusion proteins-albumin
MA53498A (fr)	2021-07-07	Production de protéines recombinantes
DK3774761T3 (da)	2024-12-02	Fremgangsmåde til fremstilling af substituerede cyclohexanaminosyreestere og spiroketalsubstituerede cykliske ketoenoler
DK3665133T3 (da)	2021-08-23	Fremgangsmåde og anlæg til fremstilling af cement
DK3818078T3 (da)	2024-05-21	Fremgangsmåder til fremstilling af rekombinante proteiner
EP3906786C0 (en)	2025-08-13	METHOD FOR PREPARING SMALL PARTICLE-SIZED PROTEIN COMPOSITIONS
DK3331694T3 (da)	2020-09-14	Stort formet letvægtsmateriale og fremgangsmåde til fremstilling deraf
EP3678701A4 (en)	2021-12-01	THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
EP3377633C0 (en)	2023-06-07	PRODUCTION OF RECOMBINANT PROTEINS